180,000 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Acquired by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 180,000 shares of the company's stock, valued at approximately $3,924,000. Adage Capital Partners GP L.L.C. owned approximately 0.61% of Dianthus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $26,000. KLP Kapitalforvaltning AS bought a new position in shares of Dianthus Therapeutics in the 4th quarter valued at about $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth approximately $35,000. AlphaQuest LLC lifted its holdings in Dianthus Therapeutics by 273.1% in the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after buying an additional 3,072 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Dianthus Therapeutics during the 4th quarter worth $201,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Trading Down 0.7 %

Shares of Dianthus Therapeutics stock traded down $0.14 on Monday, reaching $21.56. 44,305 shares of the company were exchanged, compared to its average volume of 263,679. The company has a market capitalization of $692.51 million, a price-to-earnings ratio of -8.65 and a beta of 1.48. Dianthus Therapeutics, Inc. has a one year low of $13.37 and a one year high of $32.27. The company has a 50-day moving average of $19.85 and a 200 day moving average of $22.64.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million for the quarter, compared to analysts' expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on DNTH shares. Wedbush reissued an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Guggenheim restated a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.